Clinical Trial Update: Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients with Synovial Sarcoma [Phase 1, Phase 2]

View source ↗

Summary

Completed Phase 1/2 clinical trial evaluating TBI-1301, an NY-ESO-1 TCR gene-transduced autologous T cell therapy, in patients with synovial sarcoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Synovial Sarcoma

Drugs mentioned

• TBI-1301

Snippet

Sponsor: Takara Bio Inc. | Conditions: Synovial Sarcoma | Phase 1, Phase 2 | Status: COMPLETED